Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunvozertinib + itraconazole
- Development stage
- Phase 1
- Lead developer
- Dizal Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sunvozertinib (DZD9008) is an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor (TKI) discovered by Dizal Pharmaceuticals. It is designed to target a wide spectrum of EGFR mutations, including exon 20 insertion mutations (EGFRexon20ins), while maintaining selectivity over wild-type EGFR. The combination of sunvozertinib and itraconazole specifically refers to a Phase 1 drug-drug interaction (DDI) study. In this study, itraconazole, a strong CYP3A4 inhibitor, is co-administered with sunvozertinib to evaluate its impact on the drug's pharmacokinetics and metabolic profile. Sunvozertinib has received Breakthrough Therapy Designation from the FDA and approval from the NMPA for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations following platinum-based chemotherapy.
- Brand names
- Sunvo
- Other names
- DZD9008 + itraconazole
02
Targets
ABCG2 (Breast cancer resistance protein)EGFR ex20ins (Epidermal growth factor receptor exon 20 mutant)ABCB1 (P-glycoprotein)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on sunvozertinib + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunvozertinib + itraconazole.